Immunome, Inc. (NASDAQ:IMNM) Receives Consensus Rating of “Buy” from Brokerages

Immunome, Inc. (NASDAQ:IMNM) has been assigned a consensus rating of “Buy” from the seven ratings firms that are covering the company, MarketBeat reports. Seven equities research analysts have rated the stock with a buy rating. The average 1-year target price among brokers that have issued a report on the stock in the last year is $28.83.

Several research firms have recently commented on IMNM. Wedbush reaffirmed an “outperform” rating and issued a $33.00 target price on shares of Immunome in a research report on Friday, October 25th. Stephens initiated coverage on Immunome in a report on Friday, November 8th. They issued an “overweight” rating and a $30.00 target price on the stock. Finally, Piper Sandler dropped their target price on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating on the stock in a research note on Thursday, November 14th.

Insider Buying and Selling at Immunome

In related news, CFO Max Rosett sold 14,380 shares of the business’s stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $16.01, for a total transaction of $230,223.80. Following the completion of the transaction, the chief financial officer now owns 47,476 shares in the company, valued at $760,090.76. The trade was a 23.25 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Robert Lechleider bought 15,805 shares of the stock in a transaction dated Thursday, November 21st. The shares were bought at an average cost of $9.48 per share, with a total value of $149,831.40. Following the completion of the purchase, the insider now directly owns 15,805 shares of the company’s stock, valued at approximately $149,831.40. This trade represents a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders have purchased a total of 102,862 shares of company stock worth $978,045 over the last ninety days. Company insiders own 8.60% of the company’s stock.

Hedge Funds Weigh In On Immunome

A number of hedge funds and other institutional investors have recently modified their holdings of IMNM. Quest Partners LLC purchased a new stake in shares of Immunome during the 2nd quarter worth $81,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Immunome during the second quarter valued at about $97,000. Arizona State Retirement System boosted its holdings in shares of Immunome by 9.2% in the 2nd quarter. Arizona State Retirement System now owns 10,862 shares of the company’s stock valued at $131,000 after buying an additional 918 shares in the last quarter. Intech Investment Management LLC purchased a new position in shares of Immunome in the 3rd quarter worth approximately $219,000. Finally, AQR Capital Management LLC raised its stake in shares of Immunome by 34.6% during the 2nd quarter. AQR Capital Management LLC now owns 16,064 shares of the company’s stock worth $194,000 after acquiring an additional 4,129 shares in the last quarter. 44.58% of the stock is currently owned by institutional investors.

Immunome Stock Up 3.9 %

Shares of NASDAQ IMNM opened at $14.08 on Tuesday. The firm’s fifty day moving average is $12.31 and its 200 day moving average is $13.49. Immunome has a 52 week low of $6.93 and a 52 week high of $30.96. The company has a market cap of $878.83 million, a price-to-earnings ratio of -1.70 and a beta of 1.82.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.